Kezar Life Sciences Inc
Statements
Balance Sheet
All figures as the change versus the prior period, in percent. Periods without a positive comparison base stay empty.
Tick rows to compare them in a chart (up to 4)
| Line item | Q2 23 | Q3 23 | Q4 23 | Q1 24 | Q2 24 | Q3 24 | Q4 24 | Q1 25 | Q2 25 | Q3 25 | Q4 25 | Q1 26 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| – | -5.3% | -11.3% | -10.0% | -9.6% | -8.8% | -11.8% | -13.4% | -12.9% | -10.4% | -21.6% | -11.3% | |
| – | -5.3% | -10.2% | -10.3% | -9.7% | -6.7% | -12.1% | -12.5% | -13.0% | -9.7% | -19.9% | -10.8% | |
| – | -5.7% | +33.9% | -6.9% | -14.4% | +23.3% | +19.8% | -11.4% | -7.1% | +13.3% | +84.6% | -7.9% | |
| – | -7.8% | -7.7% | -10.7% | -8.7% | -9.6% | -10.9% | -13.5% | -11.8% | -10.5% | -20.3% | -7.9% | |
| – | – | -67.3% | +33.3% | -44.8% | -35.4% | -61.1% | +418.6% | -9.3% | +0.4% | -3.8% | – | |
| – | – | – | – | – | – | – | – | – | – | – | – | |
| – | – | – | – | – | – | – | – | – | – | – | – | |
| – | +7.2% | +1.0% | -10.9% | -2.6% | +2.7% | -7.6% | -20.1% | -21.9% | -14.9% | -55.4% | -58.0% | |
| – | +21.4% | +6.4% | -8.9% | +8.3% | +16.8% | -0.5% | -16.6% | -15.3% | -6.9% | -50.9% | -58.0% | |
| – | +4.1% | +4.0% | +47.3% | +32.2% | +24.5% | +19.7% | +1.6% | +45.3% | -8.6% | -80.3% | -41.8% | |
| – | +25.2% | +164.5% | -38.7% | -55.3% | +52.9% | +5.5% | -46.2% | -41.1% | -21.3% | -44.3% | -46.2% | |
| – | +0.6% | +0.6% | -12.3% | -14.0% | -16.3% | -19.5% | -24.2% | -32.2% | -47.7% | – | – | |
| – | -7.0% | -13.2% | -9.8% | -10.9% | -11.0% | -12.8% | -11.8% | -10.9% | -9.6% | -15.6% | -6.9% | |
| – | – | – | – | – | – | – | – | – | – | – | – | |
| – | +0.3% | +0.1% | +0.1% | +0.1% | +0.1% | -90.0% | +0.1% | +0.1% | +0.2% | -0.1% | +0.4% |
Data as of: August 13, 2026 · Source: fundamental data & SEC filings (annual and quarterly reports, 10-K/10-Q)
Note: pure fact-based analysis, not investment advice and not a solicitation to buy or sell. All figures without guarantee.